Secretory leukocyte protease inhibitor (SLPI) expression and tumor invasion in oral squamous cell carcinoma

American Journal of Pathology

Volumn 178, Issue 6, 2011, Pages 2866-2878

  Wen, Jie ^a   Nikitakis, Nikolaos G ^b,c   Chaisuparat, Risa ^b   Greenwell Wild, Teresa ^a   Gliozzi, Maria ^a   Jin, Wenwen ^a   Adli, Azita ^a   Moutsopoulos, Niki ^a   Wu, Tanxia ^a   Warburton, Gary ^a,d   Wahl, Sharon M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELASTASE; LIPOCORTIN 2; PLASMIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER RISK; CELL MIGRATION; CONTROLLED STUDY; ENZYME INHIBITION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MACROPHAGE; METASTASIS; MOUTH CARCINOMA; MOUTH MUCOSA; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA;

EID: 79959426526     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.02.017     Document Type: Article

References (61)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96 (Pubitemid 351521864)
2. Fukano H, Matsuura H, Hasegawa Y, Nakamura S: Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma. Head Neck 1997, 19:205-210 (Pubitemid 27185049)
3. Curino A, Patel V, Nielsen BS, Iskander AJ, Ensley JF, Yoo GH, Holsinger FC, Myers JN, El-Nagaar A, Kellman RM, Shillitoe EJ, Molinolo AA, Gutkind JS, Bugge TH: Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. Oral Oncol 2004, 40:1026-1032 (Pubitemid 39422788)
4. Ranson M, Andronicos NM: Plasminogen binding and cancer: promises and pitfalls. Front Biosci 2003, 8:S294-S304 (Pubitemid 38925421)
5. Tang CH, Wei Y: The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci 2008, 65:1916-1932
6. Duffy MJ: The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004, 10:39-49 (Pubitemid 38072742)
7. Sharma MC, Sharma M: The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 2007, 13:3568-3575 (Pubitemid 350238927)
8. Kwon M, MacLeod TJ, Zhang Y, Waisman DM: S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Front Biosci 2005, 10:300-325 (Pubitemid 40543035)
9. Brownstein C, Falcone DJ, Jacovina A, Hajjar KA: A mediator of cell surface-specific plasmin generation. Ann N Y Acad Sci 2001, 947: 143-155; discussion 155-146
10. Shi Z, Stack MS: Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem J 2007, 407:153-159 (Pubitemid 47556980)
11. Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R: Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 2004, 53:993-1000 (Pubitemid 38824158)
12. Pepper MS: Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001, 21:1104-1117 (Pubitemid 34215137)
13. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M: Tumorassociated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009, 70:325-330
14. Devoogdt N, Revets H, Ghassabeh GH, De Baetselier P: Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci 2004, 1028:380-389 (Pubitemid 40361839)
15. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM: Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006, 7:167-174 (Pubitemid 43159503)
16. Song X, Zeng L, Jin W, Thompson J, Mizel DE, Lei K, Billinghurst RC, Poole AR, Wahl SM: Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wallinduced arthritis. J Exp Med 1999, 190:535-542 (Pubitemid 29395381)
17. Kelly E, Greene CM, McElvaney NG: Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets 2008, 12:145-157 (Pubitemid 351284958)
18. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM: Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997, 99:894-900 (Pubitemid 27123626)
19. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, Low TB, O'Neill SJ, McElvaney NG: Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005, 202:1659-1668 (Pubitemid 41815872)
20. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell- Wild T, Hale-Donze H, McGrady G, Song XY, Wahl SM: Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 2000, 6:1147-1153
21. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, Ding A: Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002, 111:867-878 (Pubitemid 36106407)
22. Angelov N, Moutsopoulos N, Jeong MJ, Nares S, Ashcroft G, Wahl SM: Aberrant mucosal wound repair in the absence of secretory leukocyte protease inhibitor. Thromb Haemost 2004, 92:288-297 (Pubitemid 39172309)
23. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM: Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004, 200:1337-1346 (Pubitemid 39552574)
24. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995, 96:456-464
25. Malamud D, Wahl SM: The mouth: a gateway or a trap for HIV? AIDS 2010, 24:5-16
26. Sallenave JM: Secretory leukocyte protease inhibitor and elafin/ trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am J Respir Cell Mol Biol 2010, 42:635-643
27. Tian X, Shigemasa K, Hirata E, Gu L, Uebaba Y, Nagai N, O'Brien TJ, Ohama K: Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep 2004, 12:1001-1006
28. Wang N, Thuraisingam T, Fallavollita L, Ding A, Radzioch D, Brodt P: The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res 2006, 66:3062-3070
29. Sugino T, Yamaguchi T, Ogura G, Kusakabe T, Goodison S, Homma Y, Suzuki T: The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol 2007, 212:152-160 (Pubitemid 46852093)
30. Simpkins FA, Devoogdt NM, Rasool N, Tchabo NE, Alejandro EU, Kamrava MM, Kohn EC: The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis 2008, 29:466-472 (Pubitemid 351404861)
31. Warburton G, Nikitakis NG, Roberson P, Marinos NJ, Wu T, Sauk JJ Jr., Ord RA, Wahl SM: Histopathological and lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell carcinoma. J Oral Maxillofac Surg 2007, 65:475-484 (Pubitemid 46343583)
32. Anneroth G, Batsakis J, Luna M: Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res 1987, 95:229-249
33. Russolo M, Giacomarra V, Papanikolla L, Tirelli G: Prognostic indicators of occult metastases in oral cancer. Laryngoscope 2002, 112: 1320-1323
34. Sacks PG: Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck. Cancer Metastasis Rev 1996, 15:27-51 (Pubitemid 26248350)
35. Yeudall WA, Miyazaki H, Ensley JF, Cardinali M, Gutkind JS, Patel V: Uncoupling of epidermal growth factor-dependent proliferation and invasion in a model of squamous carcinoma progression. Oral Oncol 2005, 41:698-708 (Pubitemid 40981110)
36. Hajjar KA, Jacovina AT, Chacko J: An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994, 269:21191-21197
37. Paul-Brent PA, Cattley TN, Myers SP, Brooks L, Cheras PA: A rapid microtitre plate screening method for in vitro assessment of fibrinolysis: a preliminary report. Blood Coagul Fibrinolysis 2004, 15:273-278 (Pubitemid 38561558)
38. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL: Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007, 67:8865-8873 (Pubitemid 47437463)
39. Kwaan HC, McMahon B: The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009, 148:43-66
40. Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, Khan KM, Falcone DJ, Hajjar KA: Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 2004, 103:317-324 (Pubitemid 38029955)
41. Jin FY, Nathan C, Radzioch D, Ding A: Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997, 88:417-426 (Pubitemid 27131383)
42. Sawair FA, Irwin CR, Gordon DJ, Leonard AG, Stephenson M, Napier SS: Invasive front grading: reliability and usefulness in the management of oral squamous cell carcinoma. J Oral Pathol Med 2003, 32:1-9 (Pubitemid 36603927)
43. Mai J, Waisman DM, Sloane BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 2000, 1477:215-230 (Pubitemid 30119902)
44. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC: Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006, 81:146-156 (Pubitemid 44715786)
45. Singh P: Role of Annexin-II in GI cancers: interaction with gastrins/ progastrins. Cancer Lett 2007, 252:19-35 (Pubitemid 46759505)
46. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008, 34: 122-136
47. Tang CH, Wei Y: The urokinase receptor and integrins in cancer progression, Cell Mol Life Sci 2008
48. Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, Parmer RJ: Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front Biosci 2005, 10:1754-1762 (Pubitemid 40529035)
49. Gonzalez-Gronow M, Kaczowka S, Gawdi G, Pizzo SV: Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Front Biosci 2008, 13:1610-1618 (Pubitemid 351599720)
50. Esposito I, Penzel R, Chaib-Harrireche M, Barcena U, Bergmann F, Riedl S, Kayed H, Giese N, Kleeff J, Friess H, Schirmacher P: Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 2006, 208:673-685
51. Moutsopoulos NM, Wen J, Wahl SM: TGF-beta and tumors: an illfated alliance. Curr Opin Immunol 2008, 20:234-240
52. Bindhu OS, Ramadas K, Sebastian P, Pillai MR: High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head Neck 2006, 28:916-25 (Pubitemid 44497868)
53. Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D, Nagumo M: Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase- 2 and CD44. Clin Exp Metastasis 2004, 21:737-745 (Pubitemid 40755013)
54. Devoogdt N, Revets H, Kindt A, Liu YQ, De Baetselier P, Ghassabeh GH: The tumor-promoting effect of TNF-alpha involves the induction of secretory leukocyte protease inhibitor. J Immunol 2006, 177:8046-8052 (Pubitemid 44846322)
55. Ace CI, Okulicz WC: Microarray profiling of progesterone-regulated endometrial genes during the rhesus monkey secretory phase. Reprod Biol Endocrinol 2004, 2:54
56. King AE, Morgan K, Sallenave JM, Kelly RW: Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. Biochem Biophys Res Commun 2003, 310:594-599 (Pubitemid 37163706)
57. Velarde MC, Iruthayanathan M, Eason RR, Zhang D, Simmen FA, Simmen RC: Progesterone receptor transactivation of the secretory leukocyte protease inhibitor gene in Ishikawa endometrial epithelial cells involves recruitment of Kruppel-like factor 9/basic transcription element binding protein-1. Endocrinology 2006, 147:1969-1978
58. Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, Campisi G: HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988- 2007). Ann Oncol 2008, 19:1681-1690
59. Monk BJ, Tewari KS: The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol 2007, 107:S6-S13 (Pubitemid 47559077)
60. Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC: Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 2008, 82:9337-9344
61. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massague J: Mediators of vascular remodeling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770 (Pubitemid 46582040)